METTL3 silencing attenuates MI-induced cardiac fibrosis in vivo through the inactivation of cardiac fibroblasts mediated by m6A methylation of fibrosis-related genes such as small mothers against decapentaplegic homolog (SMAD) 2/3 [193]. Here, METTL3 is linked to myocardial infarction.